<img alt="Shelley and Todd Engel." src="https://npr.brightspotcdn.com/dims3/default/strip/false/crop/4032x3024+0+0/resize/4032x3024!/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Fe8%2F9c%2Fb51836a743e1982e21ce159b9d5a%2Ftodd-engel3.jpeg" /><p>Limited data regarding serious adverse effects of GLP-1 medications complicates the assessment of scientific and legal inquiries about the frequency of potential serious harms, such as blindness or pancreatitis.</p><p>(Image credit: The Engel family)</p><img src="https://media.npr.org/include/images/tracking/npr-rss-pixel.png?story=nx-s1-5996652" />
✓ AI-Debiased Article
4
Wire-neutral
provisional
✓ No loaded language, vague sourcing, or framing detected.
Lawsuits claim GLP-1 medications may cause serious health issues, but data on frequency is lacking
Lawsuits allege that GLP-1 medications may lead to serious health issues, including blindness and pancreatitis. However, there is insufficient data to determine how often these adverse effects occur.
People
Todd Engel
Annotating as
No note attached
on this article.
Original vs. Neutral
Original Headline
Ongoing lawsuits allege GLP-1s can cause serious harm. But we don't know how often
Neutral Headline
Lawsuits claim GLP-1 medications may cause serious health issues, but data on frequency is lacking